EP Patent

EP3770160A1 — Gadolinium bearing pcta-based contrast agents

Assigned to Bracco Imaging SpA · Expires 2021-01-27 · 5y expired

What this patent protects

The present invention relates to Gd(PCTA-tris-glutaric acid) complex, or a pharmaceutically acceptable salt thereof, wherein at least 50% of the complex consists of the respective enantiomer RRR, the enantiomer SSS, or a mixture of such RRR and SSS enantiomers, amide derivatives …

USPTO Abstract

The present invention relates to Gd(PCTA-tris-glutaric acid) complex, or a pharmaceutically acceptable salt thereof, wherein at least 50% of the complex consists of the respective enantiomer RRR, the enantiomer SSS, or a mixture of such RRR and SSS enantiomers, amide derivatives thereof, their preparation and the use thereof as MRI contrast agents.

Drugs covered by this patent

Patent Metadata

Patent number
EP3770160A1
Jurisdiction
EP
Classification
—
Expires
2021-01-27
Drug substance claim
No
Drug product claim
No
Assignee
Bracco Imaging SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.